Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Veligrotug - Viridian Therapeutics

Next Previous
Drug Profile

Veligrotug - Viridian Therapeutics

Alternative Names: Anti-IGF1R monoclonal antibody - Viridian Therapeutics; AVE 1642; VRDN 001; ZB 001; ZL-1108

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Developer sanofi-aventis; Viridian Therapeutics; ZAI Lab; Zenas BioPharma
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action IGF type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Graves ophthalmopathy
  • Discontinued Breast cancer; Multiple myeloma; Solid tumours

Most Recent Events

  • 28 Nov 2025 No recent reports of development identified for phase-I development in Graves-ophthalmopathy(In volunteers) in China (IV, Injection)
  • 05 Nov 2025 Viridian Therapeutics plans to launch Veligrotug in USA in mid-2026.
  • 05 Nov 2025 Viridian Therapeutics announces intention to submit MAA to EMA for Graves ophthalmopathy in the first quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top